Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 11 | Vintage Vibes

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

The Independent UK

Commission's Pfizergate loss hailed as ‘victory for transparency’

The EU Court ruled against the Commission for failing to justify its refusal to release texts between von der Leyen and Pfizer’s CEO. Critics say the Commission’s actions undermine public trust and accountability, calling for greater transparency in decision-making.

Euronews

European court delivers blow to EU Commission over Von der Leyen-Pfizer texts

The European Court of Justice has upheld a transparency challenge over undisclosed text messages between EU Commission President Ursula von der Leyen and Pfizer’s CEO during the Covid-19 vaccine negotiations.

Radio France Internationale

From analysis to the latest developments in health,
read the most diverse news in one place.

How the love story between von der Leyen and Pfizer turned sour

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

Euronews

Von der Leyen’s texts with Pfizer boss can be shared, says EU’s highest court

European court of justice says no ‘plausible explanation’ given for denying New York Times access to texts from pandemic

The Guardian - UK

EU Commission loses on all counts in Pfizergate legal case

The EU’s top court annulled the Commission’s decision to deny the newspaper New York Times access to messages exchanged between President Ursula von der Leyen and Pfizer CEO Albert Bourla, finding that the EU executive failed to plausibly explain why it does not possess the texts.

Euronews

Court rules in favor of the New York Times over texts between an EU chief and a pharma boss

A top European court says the European Commission was wrong to refuse the New York Times access to text messages sent between President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Judgment Day In EU Chief's Covid Vaccine Texts Case

A top court is to rule Wednesday on whether the EU failed the transparency test by declining to release text messages sent by Ursula von der Leyen to the head of Pfizer as the bloc tried to secure Covid vaccines.

International Business Times

Do Wall Street Analysts Like Pfizer Stock?

Pfizer has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows

AES Corp., Pfizer, and LyondelBasell are examples of stocks offering a high-yield dividend today and potential upside in the latter half of 2025

MarketBeat

From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.

The Conversation

Viagra and Mounjaro panic-buying could explain Ireland's 200% export surge to U.S.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

Fortune

Stock Index Futures Muted With Focus on U.S. JOLTs Report and Corporate Earnings

June S&P 500 E-Mini futures (ESM25) are down -0.21%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.24% this morning, pointing to a muted open on Wall Street as investors await the latest reading on U.S. job openings and a new round of corporate earnings reports.

Barchart

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Pfizer CEO Albert Bourla sees ‘a scientific renaissance’ in the U.S. amid backdrop of political threats to the future of research

Also: 90% of earnings calls mention tariffs, China says there are no talks with Washington on trade.

The Independent UK

Novavax says its COVID-19 shot is on track for full FDA approval after delay

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

Barchart

This Dividend Stock Yields Nearly 8% and Trades at Depressed Valuations: Time to Buy?

Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside.

Barchart

Zimmer Biomet Hits 34th 52-Week Low: Value Play or Value Trap?

Zimmer Biomet hit its 34th 52-week low on Tuesday. Its shares have decreased by over 20% in the past year. Trading at just 11.8x the 2025 EPS estimate, the maker of orthopedic medical devices looks cheap.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pfizer will end development of weight-loss pill over fears about its impact to the liver

The drugmaker said the patient’s injury ‘resolved’ after they stopped taking the drug

Euronews

Pfizer stops working on potential pill to treat obesity after study participant has liver injury

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury.

International Business Times

Trump Tariffs Unnerve Locals In Irish 'Pharma' Hub

Vast pharmaceutical factories pepper the green landscape in southern Ireland, but the wind turbines next to the plants outside Cork are in the eye of Donald Trump's global trade storm.

Barchart

3 Unusally Active Long-Haul Call Options to Buy From Wednesday’s Wild Ride

Yesterday’s S&P 500 move from 4,950 to 5,456.90 at the close was one for the ages. The 90-day pause lit a fire under investors. These three unusually active long-haul call options stood out.

Barchart

Huge Unusual Trading in Pfizer Put Options Signals Investors' Bearish Outlook

Large, unusual trading volume in Pfizer put options is accruing today, signaling a bearish outlook by institutional investors in PFE stock. This undoubtedly relates to the Chinese tariffs, and investors' concerns.

The Guardian - UK

‘Half the place would be blown to bits’: the Irish villages under threat from Trump’s tariffs

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

Fortune

Trump tariffs could soften one of Europe’s most expensive housing markets—if tech workers face layoffs

Tech and pharma employees in Ireland are at risk from an escalating Trump trade war.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

2,050 stories

Pfizer

1,795 stories

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.